Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia.
Hurabielle C, Leboeuf C, Ram-Wolff C, Meignin V, Rivet J, Vignon-Pennamen MD, Bonnafous C, Sicard H, Fite C, Raffoux E, Arnulf B, Oksenhendler E, Sicre de Fontbrune F, Peffault de Latour R, Socié G, Bouaziz JD, Lebbé C, Bensussan A, Janin A, Bagot M, Battistella M. Hurabielle C, et al. Among authors: bonnafous c. Br J Dermatol. 2018 Jul;179(1):197-199. doi: 10.1111/bjd.16322. Epub 2018 May 9. Br J Dermatol. 2018. PMID: 29315492 No abstract available.
Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies.
Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S, Cendron D, Gross E, Lepage JF, Quillet-Mary A, Ysebaert L, Laurent G, Sicard H, Fournié JJ. Gertner-Dardenne J, et al. Among authors: bonnafous c. Blood. 2009 May 14;113(20):4875-84. doi: 10.1182/blood-2008-08-172296. Epub 2009 Mar 10. Blood. 2009. PMID: 19278954 Free article.
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M, Whittaker S, Rotolo F, Ram-Wolff C, Khodadoust MS, Bensussan A, Paturel C, Bonnafous C, Sicard H, Azim HA Jr, Kim YH. Bagot M, et al. Among authors: bonnafous c. Lancet Oncol. 2019 Aug;20(8):1160-1170. doi: 10.1016/S1470-2045(19)30320-1. Epub 2019 Jun 25. Lancet Oncol. 2019. PMID: 31253572 Clinical Trial.
KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target.
Cheminant M, Lhermitte L, Bruneau J, Sicard H, Bonnafous C, Touzart A, Bourbon E, Ortonne N, Genestier L, Gaulard P, Palmic P, Suarez F, Frenzel L, Naveau L, Bazarbachi A, Dussiot M, Waast L, Avettand-Fenoel V, Brouzes C, Pique C, Lepelletier Y, Asnafi V, Marçais A, Hermine O. Cheminant M, et al. Among authors: bonnafous c. Blood. 2022 Sep 29;140(13):1522-1532. doi: 10.1182/blood.2022016765. Blood. 2022. PMID: 35687761 Free article. Clinical Trial.
KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.
Decroos A, Cheminant M, Bruneau J, Carras S, Parinet V, Pelletier L, Lacroix L, Martin N, Giustiniani J, Lhermitte L, Asnafi V, Battistella M, Lemonnier F, De Leval L, Sicard H, Bonnafous C, Gauthier L, Genestier L, Caruso S, Gaulard P, Hermine O, Ortonne N. Decroos A, et al. Among authors: bonnafous c. Haematologica. 2023 Oct 1;108(10):2830-2836. doi: 10.3324/haematol.2022.282220. Haematologica. 2023. PMID: 37165836 Free PMC article. No abstract available.
32 results